The Patent Finder

Mycomagic Biotechnology Co., Ltd.

12 patents currently held · Updated Nov 17, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Dec 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 20, 2027
    The maintenance fee for Truncated glyceraldehyde-3-phosphate dehydrogenase promoter (US 9,163,250) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,759,100Carboxin resistance gene for Flammulina velutipes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,973,215Method for the introduction of a heterologous polynucleotide into a mushroom
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,777,021Gylceraldehyde-3-phosphate dehydrogenase promoter and heterologous gene expression
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,163,250Truncated glyceraldehyde-3-phosphate dehydrogenase promoter
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,827,288Method for treating a refractory or relapsed lung cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,975,931Use of an immunomodulatory protein from Ganoderma in promoting neurite outgrowth
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,937,226Use of immunomodulatory protein from ganoderma in inhibiting cancer stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,058,746Use of immunomodulatory protein from Ganoderma in inhibiting fibrosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,077,168Use of an immunomodulatory protein in reducing damage caused by fine particulate matter
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,141,458Composition and methods for promoting and treating chronic wound healing
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 3 patents in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited